|
M.L. Maximov
Angiotensin II receptor blocker valsartan and angiotensin-converting enzyme inhibitor enalapril in hypertensive patients with renal transpalant nephropathy
|
№5 / 2010
|
|
L.V. Podorolskaya, E.L. Tchumakova, L.V. Lobanova, L.A. Alexeeva
Fibrinolytic activity of the urine in patients with arterial hypertension with different efficacy of antihypertensive treatment
|
№5 / 2010
|
|
E.A. Saginova, A.D. Aksiutin, T.N. Krasnova, V.V. Fomin, N.A. Moukhin
Peculiarities of IgA-nephropathy clinical course, associated with excess body mass weight
|
№5 / 2010
|
|
I.E. Chazova, V.V. Fomin
European Society of Hypertension Guidelines 2009: what is changed?
|
№4 / 2010
|
|
*
Low birth weight as a risk factor for chronic kidney disease
|
№3 / 2010
|
|
V.V. Fomin, S.S. Girina
Perspectives on long-acting dihydropiridine calcium antagonists in treatment and prophylaxis of chronic kidney disease
|
№2 / 2010
|
|
B.Z. Sirotin, K.V. Zhmerenetskii, E.V. Zhmerenetskaya
State of microcirculation and microalbuminuria in patients with arterial hypertension
|
№2 / 2010
|
|
V.V. Fomin, M.A. Rasuvaeva
What is the real target blood pressure in patients with arterial hypertension without diabetes mellitus type 2?
|
№1 / 2010
|
|
S.V. Moisseev, V.V. Fomin
Loop diuretics in arterial hypertension treatment: forgotten past or bright future?
|
№1 / 2010
|
|
L.A. Alekseeva, L.A. Popova, I.V. Ryzhenkova
Arterial hypertension and chronic renal failure in patients on long-term ambulatory management
|
№1 / 2010
|
|
M.L. Nanchikeeva, L.V. Kozlovskaya, V.V. Fomin, I.N. Bobkova, V.V. Rameev
Clinical significance of determination or urinary concentration of endothelial dysfunction and fibrogenesis markers in hypertensive nephropathy
|
№4 / 2009
|
|
A.S. Donskov
Ambulatory blood pressure monitoring in patients with arterial hypertension stages I – II with uric acid metabolism abnormalities
|
№4 / 2009
|
Русский
